Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NWL6
UPID:
ASND1_HUMAN
Alternative names:
HCV NS3-transactivated protein 1
Alternative UPACC:
Q9NWL6; D3DPH6; Q3LIC3; Q4ZG45
Background:
Asparagine synthetase domain-containing protein 1, also known as HCV NS3-transactivated protein 1, plays a crucial role in cellular processes. Its involvement in the synthesis of asparagine, an amino acid essential for the biosynthesis of proteins, underscores its importance in metabolic pathways.
Therapeutic significance:
Understanding the role of Asparagine synthetase domain-containing protein 1 could open doors to potential therapeutic strategies. Its critical function in amino acid synthesis makes it a potential target for interventions in metabolic disorders.